ORGANOGENESIS HOLDINGS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $4.46 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-05-07
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $4.46M, a 8.68% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was -$9.00K.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $46.00K, a 2.13% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $4.92M, a 18.98% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $4.14M, a 32.69% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $3.12M, a 49.71% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $2.08M, a 156.09% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-03-31 | $4.46M 10-Q · filed 2026-05-07 | $4.45M derived: sum of 2 quarters · filed 2026-05-07 | $4.50M derived: sum of 3 quarters · filed 2026-05-07 | $4.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.00K derived: sum of 2 quarters · filed 2026-02-26 | $37.00K derived: sum of 3 quarters · filed 2026-02-26 | $4.92M 10-K · filed 2026-02-26 |
| 2025-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $46.00K derived: sum of 2 quarters · filed 2025-11-06 | $4.93M 10-Q · filed 2025-11-06 | $4.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.88M 10-Q · filed 2025-08-07 | $4.88M derived: sum of 3 quarters · filed 2026-05-07 | $4.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $4.88M 10-Q · filed 2026-05-07 | $4.88M derived: sum of 2 quarters · filed 2026-05-07 | $4.93M derived: sum of 3 quarters · filed 2026-05-07 | $5.35M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.00K derived: sum of 2 quarters · filed 2026-02-26 | $467.00K derived: sum of 3 quarters · filed 2026-02-26 | $4.14M 10-K · filed 2026-02-26 |
| 2024-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $467.00K derived: sum of 2 quarters · filed 2025-11-06 | $4.14M 10-Q · filed 2025-11-06 | $4.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $420.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.09M 10-Q · filed 2025-08-07 | $4.09M derived: sum of 3 quarters · filed 2026-02-26 | $4.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.67M 10-Q · filed 2025-05-08 | $3.67M derived: sum of 2 quarters · filed 2026-02-26 | $3.72M derived: sum of 3 quarters · filed 2026-02-26 | $4.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.00K derived: sum of 2 quarters · filed 2026-02-26 | $464.00K derived: sum of 3 quarters · filed 2026-02-26 | $3.12M 10-K · filed 2026-02-26 |
| 2023-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $464.00K derived: sum of 2 quarters · filed 2023-11-09 | $3.12M 10-Q · filed 2023-11-09 | $3.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.07M 10-Q · filed 2023-08-09 | $3.07M derived: sum of 3 quarters · filed 2024-02-29 | $3.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $2.65M 10-Q · filed 2023-05-10 | $2.65M derived: sum of 2 quarters · filed 2024-02-29 | $2.71M derived: sum of 3 quarters · filed 2024-02-29 | $3.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $53.00K derived: sum of 2 quarters · filed 2024-02-29 | $470.00K derived: sum of 3 quarters · filed 2024-02-29 | $2.08M 10-K · filed 2024-02-29 |
| 2022-09-30 | $53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $470.00K derived: sum of 2 quarters · filed 2023-11-09 | $2.08M 10-Q · filed 2023-11-09 | $2.30M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.03M 10-Q · filed 2023-08-09 | $2.25M derived: sum of 3 quarters · filed 2023-08-09 | $2.26M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.61M 10-Q · filed 2023-05-10 | $1.83M derived: sum of 2 quarters · filed 2023-05-10 | $1.84M derived: sum of 3 quarters · filed 2023-05-10 | $2.28M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $227.00K derived: sum of 2 quarters · filed 2023-03-01 | $670.00K derived: sum of 3 quarters · filed 2023-03-01 | $813.00K 10-K · filed 2023-03-01 |
| 2021-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $449.00K derived: sum of 2 quarters · filed 2022-11-09 | $592.00K 10-Q · filed 2022-11-09 | $883.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $443.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $586.00K 10-Q · filed 2022-08-09 | $877.00K derived: sum of 3 quarters · filed 2022-08-09 | $1.05M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $143.00K 10-Q · filed 2022-05-10 | $434.00K derived: sum of 2 quarters · filed 2022-05-10 | $612.00K derived: sum of 3 quarters · filed 2022-05-10 | $677.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $469.00K derived: sum of 2 quarters · filed 2022-03-01 | $534.00K derived: sum of 3 quarters · filed 2022-03-01 | $678.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $178.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $243.00K derived: sum of 2 quarters · filed 2021-11-09 | $387.00K 10-Q · filed 2021-11-09 | $928.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $209.00K 10-Q · filed 2021-08-09 | $750.00K derived: sum of 3 quarters · filed 2021-08-09 | $944.00K derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $144.00K 10-Q · filed 2021-05-11 | $685.00K derived: sum of 2 quarters · filed 2021-05-11 | $879.00K derived: sum of 3 quarters · filed 2021-05-11 | $957.00K derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $541.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $735.00K derived: sum of 2 quarters · filed 2021-03-16 | $813.00K derived: sum of 3 quarters · filed 2021-03-16 | $1.08M 10-K · filed 2021-03-16 |
| 2019-09-30 | $194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $272.00K derived: sum of 2 quarters · filed 2020-11-09 | $538.00K 10-Q · filed 2020-11-09 | $998.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $344.00K 10-Q · filed 2020-08-10 | $804.00K derived: sum of 3 quarters · filed 2020-08-10 | $1.01M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $266.00K 10-Q · filed 2020-05-11 | $726.00K derived: sum of 2 quarters · filed 2020-05-11 | $932.00K derived: sum of 3 quarters · filed 2020-05-11 | |
| 2018-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $666.00K derived: sum of 2 quarters · filed 2020-03-09 | $963.00K 10-K · filed 2020-03-09 | |
| 2018-09-30 | $206.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $503.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $297.00K 10-Q · filed 2019-08-09 | |||
| 2017-12-31 | $1.07M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |